The Canadian Cardiovascular Society/Canadian Heart Failure Society’s Heart Failure Guidelines are among the first to recommend that SGLT2 inhibitors be prescribed in patients with HFrEF (LVEF < 40%) and without concomitant DM, to improve symptoms and quality of life and to reduce the risk of hospitalisation and cardiovascular mortality [20]. Here, SLC5A2 is linked to heart failure.